Clopidogrel effectively inhibits platelet aggregation via ADP receptor blockade, making it preferable for atherosclerotic cardiovascular diseases. Vorapaxar targets protease-activated receptors, better for preventing recurrence in myocardial infarction patients.

Clopidogrel is suited for patients at risk for stroke or heart attack due to its antiplatelet action. Vorapaxar benefits those with a history of heart disease but may increase bleeding risk, making patient selection critical.